Danaher Co. (NYSE:DHR) Shares Bought by Scientech Research LLC

Scientech Research LLC grew its stake in shares of Danaher Co. (NYSE:DHR) by 185.4% in the second quarter, Holdings Channel.com reports. The fund owned 6,656 shares of the conglomerate’s stock after purchasing an additional 4,324 shares during the period. Scientech Research LLC’s holdings in Danaher were worth $1,663,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Gilbert & Cook Inc. raised its position in shares of Danaher by 4.9% during the 4th quarter. Gilbert & Cook Inc. now owns 1,830 shares of the conglomerate’s stock worth $423,000 after purchasing an additional 86 shares during the last quarter. Accretive Wealth Partners LLC raised its position in shares of Danaher by 12.9% during the 4th quarter. Accretive Wealth Partners LLC now owns 3,632 shares of the conglomerate’s stock worth $840,000 after purchasing an additional 414 shares during the last quarter. Gryphon Financial Partners LLC raised its position in shares of Danaher by 19.1% during the 4th quarter. Gryphon Financial Partners LLC now owns 2,917 shares of the conglomerate’s stock worth $675,000 after purchasing an additional 468 shares during the last quarter. Cape Investment Advisory Inc. acquired a new position in shares of Danaher during the 4th quarter worth approximately $25,000. Finally, Focus Financial Network Inc. ADV acquired a new position in shares of Danaher during the 4th quarter worth approximately $2,435,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DHR has been the subject of several recent analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Danaher in a research note on Friday, September 6th. Robert W. Baird lifted their target price on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. The Goldman Sachs Group lifted their target price on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. TD Cowen lifted their target price on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Finally, Stifel Nicolaus lifted their target price on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $278.94.

Insiders Place Their Bets

In other news, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the sale, the chief financial officer now owns 29,407 shares in the company, valued at approximately $8,229,254.88. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares of the company’s stock, valued at $27,435,240. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock worth $11,042,433 in the last quarter. 11.10% of the stock is owned by corporate insiders.

Danaher Trading Up 3.4 %

NYSE:DHR opened at $276.93 on Friday. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70. The business’s 50-day moving average is $269.59 and its two-hundred day moving average is $257.68. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The firm has a market capitalization of $205.12 billion, a PE ratio of 46.94, a price-to-earnings-growth ratio of 4.55 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the company posted $2.05 EPS. Danaher’s revenue for the quarter was down 2.9% on a year-over-year basis. Research analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be paid a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.